Cargando…

Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy

Background and objectives: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detachment refractory to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Alan Y., Lin, Chih-Ying, Lin, Chun-Ju, Lai, Chun-Ting, Hsia, Ning-Yi, Lin, Jane-Ming, Tien, Peng-Tai, Meng, Ping-Ping, Ku, Wei-Ning, Chen, Wen-Lu, Tsai, Yi-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784980/
https://www.ncbi.nlm.nih.gov/pubmed/36556905
http://dx.doi.org/10.3390/medicina58121703
_version_ 1784857941689499648
author Hsu, Alan Y.
Lin, Chih-Ying
Lin, Chun-Ju
Lai, Chun-Ting
Hsia, Ning-Yi
Lin, Jane-Ming
Tien, Peng-Tai
Meng, Ping-Ping
Ku, Wei-Ning
Chen, Wen-Lu
Tsai, Yi-Yu
author_facet Hsu, Alan Y.
Lin, Chih-Ying
Lin, Chun-Ju
Lai, Chun-Ting
Hsia, Ning-Yi
Lin, Jane-Ming
Tien, Peng-Tai
Meng, Ping-Ping
Ku, Wei-Ning
Chen, Wen-Lu
Tsai, Yi-Yu
author_sort Hsu, Alan Y.
collection PubMed
description Background and objectives: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detachment refractory to previous anti-vascular endothelial growth factor (anti-VEGF) therapy. Material and methods: In this retrospective study, all eyes received a single IVI-B (6 mg/0.05 mL) for wAMD or PCV with treatment-resistant SRF or PED. Outcome measures included assessment in central retinal thickness (CRT), visual acuity, and evaluation for changes in the SRF or PED on OCT. Follow-up was prior to the first brolucizumab injection, then at 1 week and 5 weeks afterwards. Results: In total, 10 eyes of 10 patients (6 women [60%]) were enrolled. Five patients had wAMD and five patients had PCV. Average age of participants was 67.6 years. All patients received one IVI-B. All patients were not treatment-naïve to anti-VEGF agents. At the first week and fifth week following the first IVI-B, seven out of seven patients (100%) had resolved SRF. However, seven out of nine patients (78%) had no improvement of their PED at 5 weeks follow-up. Mean PED height and width before the first IVI-B was 339.77 µm and 2233.44 µm, respectively. Mean PED height and width at the fifthweek following the first IVI-B was 328.125 µm and 2129.5 µm, respectively. Overall mean visual acuity before the first IVI-B was 0.224; and 5 weeks following the first IVI-B was 0.38. Conclusions: Treatment with brolucizumab resulted in anatomical improvement for all patients with persistent SRF. Limited efficacy was seen for persistent PED. Brolucizumab appears to be a safe and effective option for treatment-resistant SRF. Future multicenter collaborative studies are warranted.
format Online
Article
Text
id pubmed-9784980
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97849802022-12-24 Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy Hsu, Alan Y. Lin, Chih-Ying Lin, Chun-Ju Lai, Chun-Ting Hsia, Ning-Yi Lin, Jane-Ming Tien, Peng-Tai Meng, Ping-Ping Ku, Wei-Ning Chen, Wen-Lu Tsai, Yi-Yu Medicina (Kaunas) Article Background and objectives: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detachment refractory to previous anti-vascular endothelial growth factor (anti-VEGF) therapy. Material and methods: In this retrospective study, all eyes received a single IVI-B (6 mg/0.05 mL) for wAMD or PCV with treatment-resistant SRF or PED. Outcome measures included assessment in central retinal thickness (CRT), visual acuity, and evaluation for changes in the SRF or PED on OCT. Follow-up was prior to the first brolucizumab injection, then at 1 week and 5 weeks afterwards. Results: In total, 10 eyes of 10 patients (6 women [60%]) were enrolled. Five patients had wAMD and five patients had PCV. Average age of participants was 67.6 years. All patients received one IVI-B. All patients were not treatment-naïve to anti-VEGF agents. At the first week and fifth week following the first IVI-B, seven out of seven patients (100%) had resolved SRF. However, seven out of nine patients (78%) had no improvement of their PED at 5 weeks follow-up. Mean PED height and width before the first IVI-B was 339.77 µm and 2233.44 µm, respectively. Mean PED height and width at the fifthweek following the first IVI-B was 328.125 µm and 2129.5 µm, respectively. Overall mean visual acuity before the first IVI-B was 0.224; and 5 weeks following the first IVI-B was 0.38. Conclusions: Treatment with brolucizumab resulted in anatomical improvement for all patients with persistent SRF. Limited efficacy was seen for persistent PED. Brolucizumab appears to be a safe and effective option for treatment-resistant SRF. Future multicenter collaborative studies are warranted. MDPI 2022-11-22 /pmc/articles/PMC9784980/ /pubmed/36556905 http://dx.doi.org/10.3390/medicina58121703 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hsu, Alan Y.
Lin, Chih-Ying
Lin, Chun-Ju
Lai, Chun-Ting
Hsia, Ning-Yi
Lin, Jane-Ming
Tien, Peng-Tai
Meng, Ping-Ping
Ku, Wei-Ning
Chen, Wen-Lu
Tsai, Yi-Yu
Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
title Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
title_full Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
title_fullStr Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
title_full_unstemmed Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
title_short Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
title_sort short-term effects of brolucizumab in the treatment of wet age-related macular degeneration or polypoidal choroidopathy refractory to previous anti-vascular endothelial growth factor therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784980/
https://www.ncbi.nlm.nih.gov/pubmed/36556905
http://dx.doi.org/10.3390/medicina58121703
work_keys_str_mv AT hsualany shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT linchihying shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT linchunju shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT laichunting shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT hsianingyi shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT linjaneming shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT tienpengtai shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT mengpingping shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT kuweining shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT chenwenlu shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy
AT tsaiyiyu shorttermeffectsofbrolucizumabinthetreatmentofwetagerelatedmaculardegenerationorpolypoidalchoroidopathyrefractorytopreviousantivascularendothelialgrowthfactortherapy